U.S. markets closed

Black Diamond Therapeutics, Inc. (BDTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
27.45+0.51 (+1.89%)
At close: 4:00PM EST

27.45 0.00 (0.00%)
After hours: 4:15PM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Performance Outlook
Previous Close26.94
Open27.76
Bid27.50 x 1200
Ask27.61 x 800
Day's Range26.95 - 28.60
52 Week Range17.63 - 46.25
Volume603,177
Avg. Volume328,483
Market Cap988.082M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-13.87
Earnings DateNov 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est50.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Black Diamond Therapeutics to Present at the J.P. Morgan 39th Annual Healthcare Conference
    GlobeNewswire

    Black Diamond Therapeutics to Present at the J.P. Morgan 39th Annual Healthcare Conference

    CAMBRIDGE, Mass. and NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Company’s progress at the J.P. Morgan 39th Annual Virtual Healthcare Conference on Tuesday, January 12, 2021 at 7:30 AM ET. A live webcast of the presentation can be accessed by visiting the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. A replay of the presentation will also be available and archived on the site for three weeks.About Black Diamond Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company’s proprietary technology platform, Mutation-Allostery-Pharmacology (MAP) platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families, and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations. Black Diamond was founded by David M. Epstein, Ph.D. and Elizabeth Buck, Ph.D., and, beginning in 2017, together with Versant Ventures, began building the MAP platform and chemistry discovery engine. For more information, please visit www.blackdiamondtherapeutics.com.Contacts:For Investors: Natalie Wildenradt investors@bdtherapeutics.comFor Media: Kathy Vincent (310) 403-8951 media@bdtherapeutics.com

  • Is BDTX A Good Stock To Buy Now?
    Insider Monkey

    Is BDTX A Good Stock To Buy Now?

    Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in recent weeks. On the other hand, technology hedge funds weren’t timid and registered double digit market beating gains. Financials, energy and industrial stocks aren’t doing […]

  • What Kind Of Shareholders Own Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)?
    Simply Wall St.

    What Kind Of Shareholders Own Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)?

    If you want to know who really controls Black Diamond Therapeutics, Inc. ( NASDAQ:BDTX ), then you'll have to look at...